OR23-05 Log-term Efficacy And Safety Of Transcon PTH In Adults With Hypoparathyroidism: 52-week Results From The Open-label Extension Of The Phase 3 Pathway Trial

Disclosure: B. Clarke: Advisory Board Member; Self; Ascendis Pharma, Takeda, Entera-Bio, Extend-Bio, Amolyt. Consulting Fee; Self; Ascendis Pharma, Takeda, Entera-Bio, Extend-Bio, Amolyt. Grant Recipient; Self; Ascendis Pharma, Takeda. Research Investigator; Self; Ascendis Pharma, Takeda. Other; Sel...

Descripción completa

Detalles Bibliográficos
Autores principales: Clarke, Bart, Aziz Khan, Aliya, Ruth Rubin, Mishaela, Schwarz, Peter E, Vokes, Tamara J, Shoback, Dolores M, Gagnon, Claudia, Palermo, Andrea, Abbott, Lisa G, Hofbauer, Lorenz C, Kohlmeier, Lynn, Cetani, Filomena, Phil, Susanne, An, Xuebei, Raymond Smith, Alden, Lai, Bryant, Le, John, Ukena, Jenny, Sibley, Christopher, Shu, Aimee, Rejnmark, Lars
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Bone And Mineral Metabolism
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554189/
http://dx.doi.org/10.1210/jendso/bvad114.563

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554189/
http://dx.doi.org/10.1210/jendso/bvad114.563

Ejemplares similares